Targeting and preventing the LCOR-ERα complex through anti-ER therapies or genetic mutation of the LCOR nuclear receptor sequence (LSKAA) converts HR+ BC cold tumors into hot tumors. This evidence concerns the gene ESR1 and breast cancer.